Go Pro
→ Wall Street is staring at the wrong AI trade (From The Oxford Club) (Ad)tc pixel Free BACK Stock Alerts

IMAC (BACK) Competitors

IMAC logo
$0.0005 0.00 (0.00%)
As of 08/12/2026 03:50 PM Eastern
Compare

BACK vs. AONCW, BTSGU, WGSWW, LFMDP, and NIVFW

Should you buy IMAC stock or one of its competitors? IMAC's main competitors and comparable companies include American Oncology Network (AONCW), BrightSpring Health Services (BTSGU), GeneDx (WGSWW), LifeMD (LFMDP), and NewGenIvf Group (NIVFW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does IMAC compare to American Oncology Network?

IMAC (NASDAQ:BACK) and American Oncology Network (NASDAQ:AONCW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

American Oncology Network has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K0.03-$9.42M-$3.12N/A
American Oncology Network$1.34BN/AN/AN/AN/A

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, IMAC had 7 more articles in the media than American Oncology Network. MarketBeat recorded 7 mentions for IMAC and 0 mentions for American Oncology Network. IMAC's average media sentiment score of 0.40 beat American Oncology Network's score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company Overall Sentiment
IMAC Neutral
American Oncology Network Neutral

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
American Oncology Network N/A N/A N/A

Summary

IMAC beats American Oncology Network on 4 of the 6 factors compared between the two stocks.

How does IMAC compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSGU) and IMAC (NASDAQ:BACK) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

BrightSpring Health Services has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BrightSpring Health Services$14.37BN/AN/AN/AN/A
IMAC$72.05K0.03-$9.42M-$3.12N/A

5.8% of IMAC shares are held by institutional investors. 12.3% of IMAC shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
BrightSpring Health ServicesN/A N/A N/A
IMAC N/A N/A -325.44%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BrightSpring Health Services
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, IMAC had 5 more articles in the media than BrightSpring Health Services. MarketBeat recorded 7 mentions for IMAC and 2 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 0.96 beat IMAC's score of 0.40 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company Overall Sentiment
BrightSpring Health Services Positive
IMAC Neutral

Summary

BrightSpring Health Services beats IMAC on 4 of the 7 factors compared between the two stocks.

How does IMAC compare to GeneDx?

IMAC (NASDAQ:BACK) and GeneDx (NASDAQ:WGSWW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

In the previous week, IMAC had 7 more articles in the media than GeneDx. MarketBeat recorded 7 mentions for IMAC and 0 mentions for GeneDx. IMAC's average media sentiment score of 0.40 beat GeneDx's score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company Overall Sentiment
IMAC Neutral
GeneDx Neutral

GeneDx has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K0.03-$9.42M-$3.12N/A
GeneDx$442.68MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
GeneDx N/A N/A N/A

5.8% of IMAC shares are held by institutional investors. 12.3% of IMAC shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IMAC beats GeneDx on 4 of the 6 factors compared between the two stocks.

How does IMAC compare to LifeMD?

IMAC (NASDAQ:BACK) and LifeMD (NASDAQ:LFMDP) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

LifeMD has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K0.03-$9.42M-$3.12N/A
LifeMD$191.59MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
LifeMD N/A N/A N/A

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, IMAC had 5 more articles in the media than LifeMD. MarketBeat recorded 7 mentions for IMAC and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.94 beat IMAC's score of 0.40 indicating that LifeMD is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IMAC
0 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
LifeMD
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

IMAC and LifeMD tied by winning 3 of the 6 factors compared between the two stocks.

How does IMAC compare to NewGenIvf Group?

NewGenIvf Group (NASDAQ:NIVFW) and IMAC (NASDAQ:BACK) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, IMAC had 6 more articles in the media than NewGenIvf Group. MarketBeat recorded 7 mentions for IMAC and 1 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 1.87 beat IMAC's score of 0.40 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company Overall Sentiment
NewGenIvf Group Very Positive
IMAC Neutral

Company Net Margins Return on Equity Return on Assets
NewGenIvf GroupN/A N/A N/A
IMAC N/A N/A -325.44%

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NewGenIvf Group has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewGenIvf Group$4.73MN/AN/AN/AN/A
IMAC$72.05K0.03-$9.42M-$3.12N/A

Summary

NewGenIvf Group and IMAC tied by winning 3 of the 6 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BACK vs. The Competition

Export
MetricIMACHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2K$9.88B$6.97B$13.04B
Dividend YieldN/A2.55%2.58%10.72%
P/E Ratio0.0035.18269.8625.30
Price / Sales0.034.80601.47101.06
Price / CashN/A124.0070.5350.75
Price / Book0.005.3513.086.33
Net Income-$9.42M$309.96M$3.45B$347.70M
7 Day PerformanceN/A0.21%1.12%1.07%
1 Month PerformanceN/A0.60%1.79%1.03%
1 Year PerformanceN/A20.36%67.69%20.77%

IMAC Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BACK
IMAC
N/A$0.00
flat		N/A-99.3%$2K$72.05KN/A180
AONCW
American Oncology Network
N/A$0.00
flat		N/AN/A$0.00$1.34BN/A1,525
BTSGU
BrightSpring Health Services
N/A$205.86
+0.7%		N/A+155.3%$0.00$14.37BN/A35,000
WGSWW
GeneDx
N/A$0.00
flat		N/AN/A$0.00$442.68MN/A1,000
LFMDP
LifeMD
N/A$23.46
+0.9%		N/A-0.6%$0.00$193.33MN/A230

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BACK) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Huge AI Announcement Coming on September 3
A $51 billion backlog, a SpaceX partnership, and a presidential endorsement are fueling renewed attention on t...
InvestorPlace | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel